Cullinan reports zipalertinib study met primary endpoint
Source: SeekingAlpha
2025-01-29 12:17:55 ET
More on Cullinan Therapeutics
- Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC
- Cullinan Therapeutics: Casting A Wide Net With Their Pipeline
- Seeking Alpha’s Quant Rating on Cullinan Therapeutics
- Historical earnings data for Cullinan Therapeutics
- Financial information for Cullinan Therapeutics
Read the full article on Seeking Alpha
For further details see:
Cullinan reports zipalertinib study met primary endpoint
Otsuka Holdings Co. Ltd.
NASDAQ: OTSKF
OTSKF Trading
0.0% G/L:
$68 Last:
210 Volume:
$68 Open:
OTSKF Latest News
May 17, 2025 01:00:00 am
Innovations in High Blood Pressure Intervention Benefit Patients with Resistant Hypertension
February 06, 2025 02:00:00 pm
TANAKA to Provide Medals for the Tokyo Marathon 2025 That Represent All the Participants in the Event with Woven Lines
